MARKET

INCY

INCY

Incyte Corp
NASDAQ
114.66
+0.91
+0.80%
After Hours: 114.85 +0.19 +0.17% 16:24 06/29 EDT
OPEN
115.48
PREV CLOSE
113.75
HIGH
115.48
LOW
112.89
VOLUME
1.51M
TURNOVER
--
52 WEEK HIGH
115.56
52 WEEK LOW
66.74
MARKET CAP
22.91B
P/E (TTM)
16.21
1D
5D
1M
3M
1Y
5Y
1D
Incyte: New Catalysts Support Another Leg Higher
Seeking Alpha · 8h ago
Buy Rating Reaffirmed as Opzelura’s Global Opportunity Expands and DCF-Supported $140 Price Target Is Maintained
TipRanks · 10h ago
Weekly Report: what happened at INCY last week (0622-0626)?
Weekly Report · 10h ago
Barclays Keeps Their Buy Rating on Incyte (INCY)
TipRanks · 11h ago
1 Cash-Producing Stock with Solid Fundamentals and 2 We Turn Down
Barchart · 15h ago
Notable healthcare headlines for the week: Merck, AbbVie, and Bayer in focus
Seeking Alpha · 1d ago
What Moved Markets This Week
Seeking Alpha · 2d ago
Accenture, Estée Lauder, Luckin, Incyte, BILL Trending
TipRanks · 2d ago
More
About INCY
Incyte Corporation is a biopharmaceutical company, which is engaged in the discovery, development, and commercialization of therapeutics. The Company operates in three therapeutic areas: Hematology, Oncology, and Inflammation and Autoimmunity (IAI). Its hematology franchise includes four approved products, JAKAFI (ruxolitinib), ICLUSIG (ponatinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) and NIKTIMVO (axatilimab-csfr), as well as multiple clinical development programs. Its oncology franchise includes two approved products, PEMAZYRE (pemigatinib) and ZYNYZ (retifanlimab-dlwr), as well as several clinical development programs. Its Inflammation and Autoimmunity franchise is comprised of one approved product, OPZELURA (ruxolitinib) cream, with several clinical programs in development. The Company manages business activities on a consolidated basis through the development and commercialization of oncology and dermatology products.

Webull offers Incyte Corp stock information, including NASDAQ: INCY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, INCY stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading INCY stock methods without spending real money on the virtual paper trading platform.